Cosmetic Products Testing in the European Union
A cosmetic product which is made available on the European Union market needs to prove that it is safe for consumers. Apart from the mandatory testing, depending on the claims to be used or the type of cosmetic product to be placed on the market, additional tests may be required.
Liliana Teles

Liliana Teles

Regulatory Affairs Manager


A cosmetic product made available on the market shall be safe for human health when used under normal or reasonably foreseeable conditions of use.

According to the European Cosmetic Regulation no. 1223/2009, in order to demonstrate that a cosmetic product complies with this statement, the Responsible Person (RP) shall, before placing a cosmetic on the market, ensure that the product has undergone a safety assessment and that a Cosmetic Product Safety Report (CPSR) is made in accordance with the Regulation.

A CPSR, which shall be included in the Product Information File (PIF), must contain cosmetic product safety information (part A), which includes:

  • Qualitative and quantitative composition of the cosmetic product;
  • Physical/chemical characteristics and stability of the cosmetic product;
  • Microbiological quality;
  • Impurities, traces, information about the packaging material;
  • Normal and reasonably foreseeable use;
  • Exposure to the cosmetic product;
  • Exposure to the substances;
  • Toxicological profile of the substances;
  • Undesirable effects and serious undesirable effects;
  • Information on the cosmetic product.

So as to fulfil some of these requirements, the product/substances need to go through particular tests, which should be performed by accredited laboratories, following Good Laboratory Practices (GLP). The majority of the tests are performed with the final cosmetic product and need to be repeated if there is a change in the formula, packaging or manufacturing process.

The cosmetic product safety assessment (part B of the CPSR) is developed according to the information provided in part A and has to include the assessment conclusion, labelled warnings and instructions of use, a reasoning, the assessor’s credentials and its approval of part B.


Testing the stability of the finished cosmetic product is mandatory for an estimation of the product lifetime to be made. The stability test allows the estimation of the shelf life and the Period After Opening (PAO). In the European Union (EU) stability tests must follow the international guideline ISO/TR 18811:2018. The stability test evaluates if the product will meet the defined physical, chemical and microbiological quality standards and also evaluate its functionality, safety and aesthetics from the moment it is manufactured until the end of its use life.

The stability tests performed in accordance with ISO 18811:2018 monitor physical, chemical and microbiological specifications, organoleptic properties and packaging compatibility of the cosmetic product.

There is a wide range of different cosmetic products available on the market making it impossible to define a single way to assess product stability. The manufacturer has the responsibility to specify and justify the stability protocol to cover test methods, specifications and conditions at which the products shall be tested.

The interaction between the product and the packaging material chosen must also be evaluated. The aim is to prove an absence of migrations (e.g., ingredients, trace substances, part of the packaging) or interactions between the formula and the packaging, ensuring that no quality problems occur due to the packaging material used.

As mentioned in one of our previous posts, data on microbiological quality must be indicated in the CPSR. Moreover, “particular attention shall be paid to cosmetics used around the eyes, on mucous membranes in general, on damaged skin, on children under three years of age, on elderly people and persons showing compromised immune responses”. It is mandatory include in the CPSR the results of a preservation challenge test. This test is performed using the final cosmetic product (and prototype) to evaluate the antimicrobial protection of a cosmetic product and, consequently, ensure the correct preservation during storage and use. The microbiological quality of a cosmetic product should be assessed using the guideline ISO 17516:2014. The challenge test can be performed in accordance with ISO 11930:2012. Microbiological testing does not need to be performed on products that have low microbiologically risk (e.g., very low or very high pH).

Regarding sun care products, SPF means “sun protection factor” and it refers only to protection against the radiation which causes erythema (mainly UVB radiation) (for more information, see our previous post). Different regulations (EU, U.S, Japan, etc.) have set out different methods for testing sunscreen products and the differences between methods make it impossible to compare the SPF effectiveness, as there are no equivalent factors or tables. For this reason, an ISO standard was created (harmonized and global methodology) to ensure that all sun care products can be measured under the same conditions and ensure the safety of consumers. ISO 24444:2019 (which has updated ISO 24444:2010) sets global and harmonized guidelines for the in vivo determination of the sun protection factor (SPF) of sunscreen products. 

Besides the mandatory tests, cosmetic products can be evaluated through clinical tests in order to ensure skin compatibility or tolerance and avoid potential adverse effects in certain target groups. Human Repeated Insult Patch Tests (HRIPT), in use tests and patch/open tests are the most common clinical tests used in cosmetic products. Some companies use this type of tests in order to include claims such as “dermatologically tested” in their products.

It is also possible to perform efficacy evaluation tests of cosmetic products, which are particular important when specific claims are made (e.g., anti-ageing, anti-wrinkle, firming, non-comedogenic, etc.)

In sum, before making available a cosmetic product in the European market, it is mandatory to perform some tests: stability test; microbiological quality test; challenge test; compatibility test; SPF test (if applicable). Moreover, with the purpose of making specific claims or to demonstrate skin compatibility/tolerance, clinical tests with the final cosmetic product can be performed in human volunteers.

Placing a cosmetic product in the market may not be a simple task, but our company can help you through every step of the way. Feel free to contact us at


  1. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products.
  2. Commission Recommendation of 22 September 206 on the efficacy of sunscreen products and the claims made relating thereto. Available from:
  3. ISO/TR 18811:2018. Cosmetics – Guidelines on the stability testing of cosmetic products.
  4. ISO 11930:2019. Cosmetics – Microbiology – Evaluation of the antimicrobial protection of a cosmetic product.
  5. ISO 29621:2017. Cosmetics – Microbiology – Guidelines for the risk assessment and identification of microbiologically low-risk products.


medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »
medical devices

EUDAMED – harmonized practices and alternative solutions for IVDR until the database is fully functional

EUDAMED is one of the key aspects of the new rules on in vitro diagnostic medical devices – Regulation (EU) 2017/746. However, it is only expected to achieve full functionality by the second quarter of 2024. Until then, how is the information submitted and/or exchanged between manufacturers, notified bodies and competent authorities?

Read More »